证券代码：华大基因 证券简称：300676 深圳华大基因股份有限公司投资者关系活动记录表 编号：2024-006 | --- | --- | --- | |----------------|-----------------------------------------------------------------|----------------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 □ | 分析师会议 | | 类别 | □ 媒体采访 □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他（ 2024 | 年度深圳辖区上市公司集体接待日活动） | | 参与单位名称及 | 通过"全景路演"网站（ | https://rs.p5w.net ）采用网络远程的方式参加" 2024 | | 人员姓名 | 年度深圳辖区上市公司集体接待日"的投资者 | | | 时间 | 2024 年 12 月 12 日 ( 周四 | ) 下午 14:30~ ...

e公司讯，12月6日电，CRO概念股震荡走强，药明康德午后冲击涨停，华大基因涨超2%。 消息面上，外媒报道美国生物安全法称，美国立法者正考虑对法案进行更改，妥协版本内容包括增加对 相关公司行政审查环节，而非自动禁止生物制药公司与中国公司合作。 对此，记者以投资人身份联系了华大基因投资者关系部门，相关人士表示，"这方面我没有了解到，以 公司公告为准"。 今年9月，美国众议院通过了编号为H.R.8333的法案，即生物安全法案（The Biosecure Act）。 华大基因为被美国生物安全法案点名公司之一。 ...

华大基因：控股股东计划减持公司股份不超过2% 财联社11月25日电，华大基因公告，控股股东华大控 股计划以大宗交易方式减持公司股份不超过8,316,432股，即不超过公司总股本比例的2%。 查看公告原文 ...

好 感谢你的问题前三季度我们整个会展准备提了增加了一个多亿这个是在我们历史上看来增加金额是有史以来最高的一年确实这个跟公关经济不景气不管是企业还是政府还是医院资金链都是非常的紧张进而导致了我们的预修照法也出现了 这个增加包括这个坏账准备进一步的提升那么我们也分析了一下整个这个应求账款大概是27个亿同比增长了10%这个位置还是非常明显那么我们也做了一些细分其中这个企业客户占到应求账款是13个多亿企业客户 医院客户是13个多亿企业客户是4.7个亿政府客户有7个多亿基本上医院客户还占了一半我们的政府客户占了三分之一企业客户可能五分之一左右其实这几个也是在不同的客户的应收账款它也是分化的 我们这个风险比较大的可能是政府客户这个历史上我们的政府客户的账期大概是要一年以上那么从现在来看这个增长比较明显这个DSO账期已经增加了90天去到500多天了那么医院这一块这个这个还好我们这个 历史账期大概是八个月现在基本上增长是二十来天也在八个月九个月的这个区间里面我们企业客户控制的比较好基本上在三个月以内那么对这几块我们也做了一些分析包括我们也有具体的一些营收账款的垂收的一些措施 那么对于政府这一块 确实各地的政府财政收入下降现在 ...

证券代码：华大基因 证券简称：300676 参与单位 名 中信证券：宋硕、曾令鹏、李文涛；兴业证券：汪文博；浙商证券：司清 蕊；西南证券：陈辰；民生证券：朱凤萍；东吴证券：赵骁翔；博道基金： 称及人员 姓 高启予；中航基金：王子瑞；淡水泉投资：朱彬等 80 人。 名 深圳华大基因股份有限公司投资者关系活动记录表 编号：2024-005 | --- | --- | --- | |-------------|-----------------|----------------------| | | | | | 投资者关 系 | □ 特定对象调研 | □ 分析师会议 | | 活动类别 | □ 媒体采访 √ | 业绩说明会 | | | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | √ 其他（电话交流会） | | --- | --- | |-------------|----------------------------------------------------------------------------------------------------------------------- ...

财联社财经通讯社打开APP20:38:10【华大基因：前三季度净亏损1.24亿元】财联社10月25日电，华大 基因发布2024年第三季度报告，前三季度实现营业收入28.26亿元，同比下降10.10%；归属于上市公司 股东的净利润亏损1.24亿元。 第三季度实现营业收入9.54亿元，同比下降10.93%；归属于上市公司股东的净利润亏损1.42亿元。 华大基因+1.91%A股公告速递查看公告原文财联社声明：文章内容仅供参考，不构成投资建议。 投资者据此操作，风险自担。 2024-10-25 20:38:1014071 阅读商务合作发送 ...

Financial Performance - Revenue for the third quarter was RMB 954.49 million, a decrease of 10.93% year-over-year[2] - Net profit attributable to shareholders of the listed company was RMB -142.37 million, a decrease of 792.32% year-over-year[2] - Revenue for the first three quarters of 2024 was 2.825 billion yuan, a decrease of 10.10% year-over-year[12] - Net profit attributable to shareholders for the first three quarters of 2024 was -124.1661 million yuan, a decrease of 276.49% year-over-year[12] - Revenue for the third quarter of 2024 was 954.4853 million yuan, a decrease of 10.93% year-over-year[12] - Net profit attributable to shareholders for the third quarter of 2024 was -142.3659 million yuan, a decrease of 792.32% year-over-year[12] - Gross margin decreased by 3.07% year-over-year due to the "low-price benefit" strategy and product structure adjustments[12] - Total operating revenue for the current period was 2,825,935,926.99, a decrease from the previous period's 3,143,452,163.96[21] - Operating costs for the current period were 1,548,174,697.10, down from 1,625,482,961.92 in the previous period[21] - Net profit for the current period was -124,180,426.78, a significant decline from 70,146,749.72 in the previous period[22] Cash Flow - The company's operating cash flow for the period was RMB -142.81 million, a decrease of 178.41% year-over-year[2] - Investment cash flow for the period was RMB -527.08 million, a decrease of 608.58% year-over-year[6] - Net cash flow from operating activities was -142.81 million yuan, compared to 182.13 million yuan in the previous period[25] - Net cash flow from investing activities was -527.08 million yuan, compared to -74.39 million yuan in the previous period[25] - Net cash flow from financing activities was -316.81 million yuan, compared to -213.99 million yuan in the previous period[25] - Total cash inflow from investing activities was 7.66 billion yuan, compared to 2.80 billion yuan in the previous period[25] - Total cash outflow from investing activities was 8.19 billion yuan, compared to 2.87 billion yuan in the previous period[25] - Cash and cash equivalents at the end of the period were 2.59 billion yuan, compared to 5.10 billion yuan in the previous period[25] - Cash outflow for the purchase of fixed assets, intangible assets, and other long-term assets was 364.14 million yuan, compared to 945.82 million yuan in the previous period[25] - Cash outflow for investments was 7.82 billion yuan, compared to 1.92 billion yuan in the previous period[25] - Cash inflow from investment returns was 76.46 million yuan, compared to 230.41 million yuan in the previous period[25] - Cash outflow for debt repayment was 22.79 million yuan, compared to 6.00 million yuan in the previous period[25] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 13.28 billion, a decrease of 2.41% compared to the end of the previous year[2] - The company's long-term loans increased by 61.14% to RMB 347.54 million[6] - The company's monetary funds decreased from RMB 4,732,376,385.95 at the beginning of the period to RMB 3,779,410,999.45 at the end of the period[18] - The company's accounts receivable increased from RMB 1,443,946,645.90 at the beginning of the period to RMB 1,829,117,714.81 at the end of the period[18] - The company's total assets decreased from RMB 13,613,007,886.01 at the beginning of the period to RMB 13,284,380,251.44 at the end of the period[19] - The company's total liabilities decreased from RMB 3,608,987,599.21 at the beginning of the period to RMB 3,313,098,459.67 at the end of the period[20] - The company's total equity decreased slightly from RMB 10,004,020,286.80 at the beginning of the period to RMB 9,971,281,791.77 at the end of the period[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 65,696[7] - Shenzhen Huada Gene Technology Co., Ltd. holds 35.78% of the shares, totaling 148,773,893 shares[7] - Shenzhen Shenghua Investment Enterprise (Limited Partnership) holds 8.29% of the shares, totaling 34,470,455 shares[7] - China Merchants Bank Co., Ltd. - Wanjia Industry Preferred Hybrid Securities Investment Fund (LOF) holds 2.16% of the shares, totaling 9,000,038 shares[7] - Bank of China Limited - Huabao CSI Medical ETF holds 2.00% of the shares, totaling 8,334,173 shares[7] - Industrial and Commercial Bank of China Limited - E Fund ChiNext ETF holds 1.59% of the shares, totaling 6,603,143 shares[8] - Agricultural Bank of China Limited - CSI 500 ETF holds 1.12% of the shares, totaling 4,660,700 shares[8] - Shenzhen Huada Sanshengyuan Technology Co., Ltd. holds 0.95% of the shares, totaling 3,935,824 shares[8] - Shenzhen Huada Gene Co., Ltd. - Second Phase Employee Stock Ownership Plan holds 0.88% of the shares, totaling 3,679,441 shares[8] - Hong Kong Securities Clearing Company Limited holds 0.82% of the shares, totaling 3,411,574 shares[8] Business Segments - Reproductive health business revenue for the first three quarters of 2024 was nearly 900 million yuan, an increase of 3.7% year-over-year[13] - Tumor and chronic disease prevention business revenue for the first three quarters of 2024 was nearly 400 million yuan, an increase of 14.1% year-over-year[13] - Infection prevention and control business revenue for the first three quarters of 2024 was 53 million yuan, a decrease of 85.4% year-over-year[13] Expenses and Losses - Credit impairment losses increased by 567.63% to RMB -105.49 million[6] - The company's financial expenses decreased by 141.59% to RMB -59.12 million[6] - The company's investment income decreased by 171.72% to RMB -21.85 million[6] - The company's income tax expense decreased by 117.03% to RMB -2.84 million[6] - Credit impairment losses increased by 89.69 million yuan year-over-year due to slower accounts receivable collection[12] - Investment losses from equity method investments increased by 39.51 million yuan year-over-year[12] - R&D expenses increased to 398,014,771.10 from 388,313,454.65 in the previous period[22] - Taxes and surcharges increased to 12,759,204.55 from 7,685,898.04 in the previous period[21] - Sales expenses decreased to 663,331,251.16 from 757,102,622.30 in the previous period[21] Investments and Shareholdings - The company's directors and senior executives have cumulatively increased their shareholdings by 144,400 shares, accounting for 0.0347% of the total shares, with a total investment of RMB 5,098,552, which is more than half of the planned RMB 10 million[16] - The company invested RMB 149 million to participate in the subscription of Shaoxing Meiyue Medical Industry Equity Investment Partnership (Limited Partnership) fund, targeting the life and health sector with a planned fundraising scale of RMB 500 million[17] Operating Activities - Cash received from sales of goods and services was 2,312,310,695.98, down from 3,584,309,809.63 in the previous period[24] - Total cash inflows from operating activities were 2,541,858,433.66, compared to 3,784,255,101.26 in the previous period[24] - Cash paid for goods and services was 1,057,292,663.53, a decrease from 1,515,900,082.58 in the previous period[24] - Cash paid to employees and for employee benefits was 925,531,974.13, down from 1,050,773,258.03 in the previous period[24]

证券代码：华大基因 证券简称：300676 深圳华大基因股份有限公司投资者关系活动记录表 编号：2024-004 投资者关 系 □特定对象调研 □分析师会议 活动类别 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 √其他（电话交流会） 参与单位 名 中信证券：李文涛；兴业证券：汪文博；浙商证券：司清蕊；西南证券： 陈辰；民生证券：朱凤萍；上海睿胜投资：韩立；混沌道然：蒋晶；泓澄 称及人员 姓 投资：殷萌等 83 人。 名 时间 2024 年 8 月 26 日 16:00-17:00 地点 广东省深圳市盐田区云华路 9 号 华大时空中心会议室 总经理 赵立见；副总经理 李宁；副总经理 朱师达；副总经理、财务总监 上市公司 接 王玉珏；副总经理、董事会秘书 徐茜；副总经理 李浩；产品负责人 徐辉 待人员姓名 本次活动是深圳华大基因股份有限公司（简称公司或华大基因）在 2024 半年度报告发布后的业绩说明会，活动采用线上电话会议的形式。公 司副总经理、董事会秘书徐茜女士和副总经理、财务总监王玉珏先生首先 分别简要回顾了2024上半年华大基因的业务发展和经营业绩的整体情况， 随后公司管理层与投资者就 ...

深圳华大基因股份有限公司 2024 年半年度报告全文 深圳华大基因股份有限公司 2024 年半年度报告 2024 年 8 月 1 深圳华大基因股份有限公司 2024 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人赵立见、主管会计工作负责人王玉珏及会计机构负责人(会计 主管人员)柳慧声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及的未来发展战略与规划、经营计划与目标等前瞻性陈述，不构 成公司对投资者的实质承诺。投资者及相关人士均应对此保持足够的风险认 识，并应理解计划、预测与承诺之间的差异。公司在本报告第三节"管理层讨 论与分析"之"十、公司面临的风险和应对措施" 部分，详细描述了公司经营 中可能存在的风险及应对措施，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 深圳华大基因股份有限公司 2024 年半年度报告全文 目录 | --- | |-- ...

深圳华大基因股份有限公司 2024 年第一季度报告 □会计政策变更 □会计差错更正 同一控制下企业合并 □其他原因 证券代码：300676 证券简称：华大基因 公告编号：2024-031 深圳华大基因股份有限公司 2024 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第一季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 | --- | --- | --- | --- | --- | |------------------------------------------------------|----------------|----------------- ...